Product Development - The company is focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its proprietary "Cell-in-a-Box" technology[135]. - The current product candidate is referred to as "CypCaps™" and is intended for use in therapies for several types of cancer, including LAPC[135]. - The company is currently conducting a pilot study involving two pigs to evaluate the safety and activity of its product candidate for pancreatic cancer[145]. - The encapsulation technology aims to protect genetically engineered live human cells, enhancing their survival and efficacy in producing active molecules[136]. - The company is also developing therapies for Type 1 diabetes using encapsulated genetically modified insulin-producing cells[139]. Regulatory Challenges - Due to a clinical hold placed by the FDA on the IND for LAPC, the company is facing delays and increased costs in its development efforts[131]. - The FDA has requested additional data and studies to lift the clinical hold, including genetic stability studies and a biocompatibility assessment[144]. - The company is currently addressing various regulatory requirements to lift the clinical hold on its IND for the planned clinical trial in LAPC[152]. Financial Performance - The total operating expenses for the three months ended October 31, 2022, increased by $1,313,777 to $2,318,620 from $1,004,843 in the same period in 2021, primarily due to increases in R&D costs, compensation, legal, and consulting expenses[155]. - R&D expenses for the three months ended October 31, 2022, were $177,996, reflecting a 32% increase from $135,220 in the same period in 2021[156]. - Compensation expenses for the three months ended October 31, 2022, were $400,420, a 51% increase from $265,012 in the same period in 2021[156]. - The total operating expenses for the six months ended October 31, 2022, increased by $1,971,034 to $3,999,228 from $2,028,194 in the same period in 2021[157]. - R&D expenses for the six months ended October 31, 2022, were $337,269, a 21% increase from $278,833 in the same period in 2021[158]. - Compensation expenses for the six months ended October 31, 2022, were $728,138, a 36% increase from $533,897 in the same period in 2021[158]. - General and administrative, legal, and professional expenses for the three months ended October 31, 2022, were $1,637,869, representing a 201% increase from $543,557 in the same period in 2021[156]. - General and administrative, legal, and professional expenses for the six months ended October 31, 2022, were $2,778,759, a 155% increase from $1,091,251 in the same period in 2021[158]. - The company had no revenues for the three and six months ended October 31, 2022, and 2021[154]. Cash Flow and Liquidity - Net cash used in operating activities for the six months ended October 31, 2022, was $(2,963,642), compared to $(2,626,834) for the same period in 2021, indicating an increase in operational losses[162]. - Cash and cash equivalents as of October 31, 2022, totaled approximately $77 million, down from approximately $87 million as of October 31, 2021, primarily due to increased operating expenses and stock repurchase[165]. - The cash used in financing activities for the six months ended October 31, 2022, was approximately $(5.5 million) due to the repurchase of common stock[164]. - The company expects to use existing cash balances and may consider additional debt or equity issuances to meet liquidity needs, given the history of operating losses[171]. - The total cost of service agreements related to the clinical hold on the IND submission involving LAPC is estimated to be approximately $347,000, with a significant portion allocated to related parties[172]. - The company had no investing activities for the six months ended October 31, 2022, and 2021, indicating a focus on operational rather than investment expenditures[163]. - The company received gross proceeds of approximately $70 million from the Second Offering in August 2021, contributing to its capital resources[168]. - The company reported a net increase (decrease) in cash and cash equivalents of $(8,438,069) for the six months ended October 31, 2022, compared to an increase of $84,736,506 in the same period of 2021[162]. - The company has no off-balance sheet arrangements that could materially affect its financial condition, revenues, or expenses[170]. Corporate Governance - The company has entered into a Cooperation Agreement with Iroquois Master Fund Ltd. to reconstitute its Board and evaluate its business strategy[135]. - Spending on development programs has been curtailed pending the completion of the Business Review Committee's evaluation[142]. - The company is exploring new frameworks for its relationship with SG Austria, which may impact its development programs[135].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number 001-40699 PHARMACYTE BIOTECH, INC. (Exact name of registrant as specified in its charter) (State or othe ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number 001-40699 PHARMACYTE BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 62- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Nevada 62-1772151 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 3960 Howard Hughes Parkw ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number 001-40699 PHARMACYTE BIOTECH, INC. (Exact name of registrant as specified in its charter) (State or o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number 001-40699 PHARMACYTE BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 62-1772 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number 001-40699 PHARMACYTE BIOTECH, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number 333-68008 PHARMACYTE BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 62-1772151 (State or o ...